Literature DB >> 11948373

Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.

T Nakamura1, R Morishita, T Asai, N Tsuboniwa, M Aoki, H Sakonjo, K Yamasaki, N Hashiya, Y Kaneda, T Ogihara.   

Abstract

Transcription factor E2F plays a pivotal role in the transactivation of cell cycle regulatory genes, leading to vascular lesion formation. Double-stranded DNA with high affinity for E2F as 'decoy' cis elements may block the activation of genes mediating the cell cycle, resulting in an effective therapeutic agent for treating intimal hyperplasia. In this study, we tested the feasibility of E2F decoy therapy to treat neointimal formation in a porcine coronary artery balloon injury model. An angioplasty catheter was inserted in the left anterior descending coronary artery of pigs to cause vascular injury. Initially, we tested the feasibility of transfection of FITC-labeled E2F decoy ODN using a hydrogel balloon catheter. Fluorescence due to E2F decoy ODN could be detected throughout the medial layer. Therefore, we transfected E2F decoy ODN into the balloon-injured artery using hydrogel catheter. Of importance, intravascular ultrasound (IVUS) and histological evaluation demonstrated that plaque area in the balloon-injured artery was significantly reduced by E2F decoy ODN compared with mismatched decoy ODN at 1 month after a single transfection (P < 0.01). In contrast, luminal and total vessel areas were significantly increased in vessels treated with E2F decoy ODN as compared with mismatched decoy. Endothelial function after angioplasty was not affected by E2F decoy transfection. Finally, we tested the acute toxicity of E2F decoy ODN in monkeys, and no apparent side-effects were detected. Here, we report the successful in vivo transfer of E2F decoy ODN using a hydrogel catheter to inhibit vascular lesion formation in balloon-injured porcine coronary artery without any apparent side-effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948373     DOI: 10.1038/sj.gt.3301679

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

1.  Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.

Authors:  Di Jia; Sean M Hasso; Joanne Chan; Domenic Filingeri; Patricia A D'Amore; Lori Rice; Christine Pampo; Dietmar W Siemann; David Zurakowski; Scott J Rodig; Marsha A Moses
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

Review 2.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

3.  Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine acute myocardial infarction model.

Authors:  Hideaki Kaneda; Fumiaki Ikeno; Koichi Inagaki; Daria Mochly-Rosen
Journal:  Int J Cardiol       Date:  2008-02-01       Impact factor: 4.164

Review 4.  Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis.

Authors:  Maryam Mahjoubin-Tehran; Yong Teng; Amin Jalili; Seyed Hamid Aghaee-Bakhtiari; Alexander M Markin; Amirhossein Sahebkar
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.